Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Interleukin-2 receptor subunit beta and Cytokine receptor common subunit gamma (IL-2Rβγ) complex is the primary signaling unit for the cytokines IL-2 and IL-15. This heterodimer consists of CD122 (beta) and CD132 (gamma), which are members of the type I cytokine receptor family (UniProt P14784, P31785). Upon binding its ligand, the complex recruits Janus kinases (JAK1 and JAK3) to trigger downstream signaling through the STAT5, PI3K/AKT, and MAPK pathways. These pathways are critical for driving the expansion and activation of CD8+ T cells and Natural Killer (NK) cells (Liao et al., 2013). Unlike the high-affinity trimeric IL-2 receptor that includes the alpha subunit (CD25), the IL-2Rβγ complex is an intermediate-affinity receptor that is not constitutively expressed on regulatory T cells (Tregs). This distinction makes it a high-value target in oncology, where "biased" agonists like bempegaldesleukin and N-803 are designed to selectively engage the βγ subunits. This strategy aims to enhance anti-tumor immunity while minimizing the immunosuppression and toxicity, such as vascular leak syndrome, associated with CD25 activation (Hurwitz et al., 2021; Chamie et al., 2022). Consequently, the IL-2Rβγ complex is a focal point for developing next-generation cancer treatments and therapies for chronic viral infections.
Selective agonism of the IL-2Rβγ complex to stimulate effector T cell and NK cell proliferation and activation via the JAK/STAT signaling pathway (Liao et al., 2013; Waldmann, 2006).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-2 receptor subunit beta and Cytokine receptor common subunit gamma (IL-2Rβγ) (IL-2Rβγ).